Current status, complications and prospects of fecal microbiota transplantation therapy
Archives of Pathology and Clinical Research · 2021
DOI: 10.29328/journal.apcr.1001021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Pathology and Clinical Research, 2021. Verfasst von Tadashi Ohara. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Currently, the emergence of highly virulent mutants in Europe and the United States has caused refractory recurrent Clostridium difficile infection (RCDI) to be a problem in clinical practice. In 2013, the Netherland group demonstrated breakthrough therapeutic efficacy in fecal microbial transplant (FMT) treatment clinical trials for RCDI, and FMT treatment is rapidly gaining attention. In addition to RCDI, FMT treatment has been attempted in various gastrointestinal diseases such as inflammatory bowel disease, irritable bowel syndrome and chronic constipation, as well as extragastrointestinal diseases. In this review, I would like to describe the current status, complications and prospects of FMT treatment.
Zitieren
APA
Ohara, T. (2021). Current status, complications and prospects of fecal microbiota transplantation therapy. Archives of Pathology and Clinical Research. https://doi.org/10.29328/journal.apcr.1001021
Vancouver
Ohara T. Current status, complications and prospects of fecal microbiota transplantation therapy. Archives of Pathology and Clinical Research. 2021. doi:10.29328/journal.apcr.1001021
BibTeX
@article{Ohara2021,
author = {Ohara, Tadashi},
title = {Current status, complications and prospects of fecal microbiota transplantation therapy},
journal = {Archives of Pathology and Clinical Research},
year = {2021},
doi = {10.29328/journal.apcr.1001021}
}
EUVIMED